ISTA Pharmaceuticals Inc., of Irvine, Calif., said a paper published in RETINA, The Journal of Retinal and Vitreous Diseases, of a pilot study suggested that the topical nonsteroidal anti-inflammatory eye drop Xibrom (bromfenac ophthalmic solution) administered twice daily might have an additive effect when used with intravitreal Lucentis (ranibizumab injection, Roche AG) in reducing retinal thickness in neovascular age-related macular degeneration.